$80.24
0.41% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US2521311074
Symbol
DXCM
Sector

DexCom, Inc. Stock price

$80.24
+2.14 2.74% 1M
-34.30 29.95% 6M
-43.85 35.34% YTD
-43.49 35.15% 1Y
-62.23 43.68% 3Y
+25.71 47.16% 5Y
+66.21 471.82% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.33 0.41%
ISIN
US2521311074
Symbol
DXCM
Sector

Key metrics

Market capitalization $31.34b
Enterprise Value $31.44b
P/E (TTM) P/E ratio 48.10
EV/FCF (TTM) EV/FCF 58.77
EV/Sales (TTM) EV/Sales 7.95
P/S ratio (TTM) P/S ratio 7.93
P/B ratio (TTM) P/B ratio 15.84
Revenue growth (TTM) Revenue growth 16.19%
Revenue (TTM) Revenue $3.95b
EBIT (operating result TTM) EBIT $628.00m
Free Cash Flow (TTM) Free Cash Flow $535.00m
Cash position $2.49b
EPS (TTM) EPS $1.67
P/E forward 51.81
P/S forward 7.81
EV/Sales forward 7.83
Short interest 2.71%
Show more

Create a Free Account to create an DexCom, Inc. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

DexCom, Inc. Stock Analysis

Analyst Opinions

26 Analysts have issued a DexCom, Inc. forecast:

21x Buy
81%
5x Hold
19%

Analyst Opinions

26 Analysts have issued a DexCom, Inc. forecast:

Buy
81%
Hold
19%

Financial data from DexCom, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3,954 3,954
16% 16%
100%
- Direct Costs 1,513 1,513
22% 22%
38%
2,441 2,441
13% 13%
62%
- Selling and Administrative Expenses 1,055 1,055
5% 5%
27%
- Research and Development Expense 546 546
12% 12%
14%
840 840
24% 24%
21%
- Depreciation and Amortization 212 212
25% 25%
5%
EBIT (Operating Income) EBIT 628 628
24% 24%
16%
Net Profit 681 681
81% 81%
17%

In millions USD.

Don't miss a Thing! We will send you all news about DexCom, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DexCom, Inc. Stock News

Negative
CNBC
5 days ago
It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health companies, around two-thirds have lost value this year, while the Nasdaq is up 32%.
Positive
Reuters
5 days ago
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.
Neutral
The Motley Fool
8 days ago
Shares of the medical-device maker DexCom (DXCM 5.57%) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive drop in its stock price overnight.
More DexCom, Inc. News

Company Profile

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Sayer
Employees 9,600
Founded 1999
Website www.dexcom.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today